SkQ1 Eye Drop Stabilization Against Vial Adsorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Mitochondria-addressed antioxidants like SkQ1 face challenges in ophthalmic preparations due to their unusual physicochemical properties, leading to unpredictable concentrations and effectiveness in eye drops, as they can act as prooxidants at certain concentrations and are prone to irreversible absorption on vial surfaces, altering the composition's efficacy.
Innovation Solution
A pharmaceutical composition for eye pathologies comprising a mitochondria-addressed antioxidant, a pH buffer, a concentration stabilizer, a prolongator, and a preservative, with SkQ1-bromide as the primary antioxidant, using benzalkonium chloride as a stabilizer and hydroxypropylmethylcellulose as a prolongator to maintain stable concentrations and prevent absorption on vial surfaces.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mitochondria-addressed antioxidants are used in ophthalmic preparations, then antioxidant efficiency is improved, but concentration stability deteriorates due to irreversible absorption on vial surfaces
Solution Approach 1:
The patent introduces a stabilizer as an intermediary substance that prevents direct interaction between the mitochondria-addressed antioxidant and the vial surface. This stabilizer acts as a mediator that blocks the irreversible absorption process while allowing the antioxidant to maintain its therapeutic concentration in the eye drop formulation.
Solution Approach 2:
The patent modifies the chemical environment of the formulation by adjusting pH, ionic strength, and adding specific stabilizing agents. These parameter changes alter the interaction between the antioxidant and container surface, preventing adsorption while maintaining the antioxidant's biological activity and mitochondrial targeting capability.
2Reliability
If mitochondria-addressed antioxidants are used in ophthalmic preparations, then therapeutic effectiveness is improved, but predictability of concentration deteriorates
Solution Approach 1:
The stabilizer serves as a predictive intermediary that consistently prevents adsorption across different storage conditions and time periods. This creates a reliable and predictable concentration profile, allowing clinicians to trust that the administered dose will match the formulated dose.
Solution Approach 2:
The patent incorporates stabilizing agents that provide a feedback mechanism to maintain equilibrium. When the antioxidant concentration attempts to change due to adsorption or degradation, the stabilizer system responds to counteract these changes, maintaining a predictable and stable therapeutic concentration.
3Reliability
If certain concentrations of mitochondria-addressed antioxidants are used, then antioxidant power is improved, but prooxidant effects worsen
Solution Approach 1:
The patent carefully controls and optimizes the concentration parameters of the mitochondria-addressed antioxidant within a specific therapeutic window. By maintaining the concentration within this optimized range through the use of stabilizers and proper formulation, the system achieves maximum antioxidant efficacy while preventing the transition to prooxidant behavior that occurs at higher concentrations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively stabilizes SkQ1 concentrations, preventing irreversible absorption and maintaining therapeutic efficacy, making it suitable for treating various eye diseases by ensuring consistent delivery of the active ingredient.
Implementation Method 1
Mitochondria-addressed antioxidants that can be reduced and oxidized by the enzymes of the electron transport chain of mitochondria are one of the most effective antioxidants
Implementation Method 2
The ability of SkQ1 to be irreversibly absorbed at the surface of tubes (vials) containing eye drops was also detected
Data Source
AI summary
The invention relates to the manufacturing and use of pharmaceutical compositions of medicines (ophthalmic preparations) comprising a mitochondria-addressed antioxidant and a set of auxiliary substances providing effective treatment for ophthalmological diseases in humans and animals.